GLAXOSMITHKLINE PLC

GSK
Delayed Quote. Delayed  - 07/27 11:38:11 am
1399.2GBX -0.04%
Valuation
Fiscal Period: December 2020 2021
Capitalization1 66 80170 047
Entreprise Value (EV)1 87 58191 510
P/E ratio 11,8x20,4x
Yield 5,96%5,71%
Capitalization / Revenue 1,96x2,12x
EV / Revenue 2,57x2,77x
EV / EBITDA 9,19x9,72x
Price to Book 4,58x4,74x
Nbr of stocks (in thousands) 4 977 7315 004 075
Reference price (GBP) 13,414,0
Announcement Date 02/03/2021-
Previous period Next period
1 GBP in Million
Estimates
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2020 2021
Net sales1 34 09933 019
EBITDA1 9 5309 419
Operating profit (EBIT)1 8 9068 056
Operating Margin 26,1%24,4%
Pre-Tax Profit (EBT)1 6 9685 391
Net income1 5 7493 385
Net margin 16,9%10,3%
EPS2 1,140,69
Dividend per Share2 0,800,80
Announcement Date 02/03/2021-
Previous period Next period
1 GBP in Million
2 GBP
Finances - Leverage
Fiscal Period: December 2020 2021
Net Debt1 20 78021 463
Net Cash position1 --
Leverage (Debt / EBITDA) 2,18x2,28x
Free Cash Flow1 5 4064 227
ROE (Net Profit / Equities) 44,4%33,6%
Shareholders' equity1 12 95110 062
ROA (Net Profit / Asset) 7,18%4,82%
Assets1 80 06270 248
Book Value Per Share2 2,932,95
Cash Flow per Share2 1,681,02
Capex1 1 2261 362
Capex / Sales 3,60%4,12%
Announcement Date 02/03/2021-
Previous period Next period
1 GBP in Million
2 GBP
Financial Ratios
Size 2021e 2022e
Capitalization 70 047 M GBP -
Entreprise Value (EV) 91 510 M GBP 90 183 M GBP
Valuation 2021e 2022e
P/E ratio (Price / EPS) 20,4x 16,2x
Capitalization / Revenue 2,12x 2,01x
EV / Revenue 2,77x 2,63x
EV / EBITDA 9,72x 8,83x
Yield (DPS / Price) 5,71% 4,08%
Price to book (Price / BVPS) 4,74x 4,49x
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) 24,4% 25,7%
Operating Leverage (Delta EBIT / Delta Sales) -3,01x 2,02x
Net Margin (Net Profit / Revenue) 10,3% 12,4%
ROA (Net Profit / Asset) 4,82% 5,82%
ROE (Net Profit / Equities) 33,6% 36,0%
Rate of Dividend 117% 66,1%
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   4,12% 4,05%
Cash Flow / Sales 15,5% 18,7%
Capital Intensity (Assets / Sales) 2,13x 2,13x
Financial Leverage (Net Debt / EBITDA) 2,28x 1,94x
Price Earning Ratio
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS & Dividend